Despite their low prevalence, genetic kidney diseases (GKD) still represent a serious health problem. They often lead to kidney failure and to the consequent need of dialysis or kidney transplant. To date, reliable diagnosis requires laborious genetic tests and/or a renal biopsy. Moreover, only scant and non-specific markers exist for prognostic purposes. Biomarkers assayed in an easily available and low-cost sample, such as urine, would be highly valuable. Urinary proteomics can provide clues related to their development through the identification of differentially expressed proteins codified by the affected genes, or other dis-regulated species, in total or fractionated urine, providing novel mechanistic insights. In this review, the authors summarize and discuss the results of the main proteomic investigations on GKD urine samples and in urinary extracellular vesicles.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/14789450.2016.1136218 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neuro-reproductive toxicity and carcinogenicity of 1-bromopropane - studies for evidence-based preventive medicine (EBPM).
J Occup Health
January 2025
Department of Occupational and Environmental Health, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Japan.
Bromopropane was introduced commercially as an alternative to ozone-depleting and global warming solvents. The identification of 1-bromopropane neurotoxicity in animal experiments was followed by reports of human cases of 1-bromopropane toxicity. In humans, the most common clinical features of 1-bromopropane neurotoxicity are decreased sensation, weakness in extremities, and walking difficulties.
View Article and Find Full Text PDFStandard operating procedure combined with comprehensive quality control system for multiple LC-MS platforms urinary proteomics.
Nat Commun
January 2025
School of Biological Science and Medical Engineering & School of Engineering Medicine, Beihang University, Beijing, China.
Urinary proteomics is emerging as a potent tool for detecting sensitive and non-invasive biomarkers. At present, the comparability of urinary proteomics data across diverse liquid chromatography-mass spectrometry (LC-MS) platforms remains an area that requires investigation. In this study, we conduct a comprehensive evaluation of urinary proteome across multiple LC-MS platforms.
View Article and Find Full Text PDFActivity of Various Cathepsin Proteases and Enrichment of Klotho Protein in the Urine and Urinary Extracellular Vesicles After SARS-CoV-2 Infection.
Viruses
December 2024
Department of Medicine, Division of Nephrology, Hypertension, and Renal Transplantation, University of Florida College of Medicine, Gainesville, FL 32608, USA.
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for causing the Coronavirus disease 2019 (COVID-19) outbreak. While mutations cause the emergence of new variants, the ancestral SARS-CoV-2 strain is unique among other strains. Various clinical parameters, the activity of cathepsin proteases, and the concentration of various proteins were measured in urine samples from COVID-19-negative participants and COVID-19-positive participants.
View Article and Find Full Text PDFUrinary Proteome and Exosome Analysis Protocol for the Discovery of Respiratory Diseases Biomarkers.
Biomolecules
January 2025
BioLympho Research Group, Department of Biochemistry and Molecular Biology, Faculty of Biology-Biological Research Centre (CIBUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, Spain.
This study aims to develop a protocol for respiratory disease-associated biomarker discovery by combining urine proteome studies with urinary exosome components analysis (i.e., miRNAs).
View Article and Find Full Text PDFUrinary Proteomic Shifts over Time and Their Associations with eGFR Decline in Chronic Kidney Disease.
Biomolecules
January 2025
Department of Medicine, School of Medicine, Nazarbayev University, Astana 010000, Kazakhstan.
Chronic kidney disease (CKD) is a progressive condition characterized by declining renal function, with limited biomarkers to predict its progression. The early identification of prognostic biomarkers is crucial for improving patient care and therapeutic strategies. This follow-up study investigated urinary proteomics and clinical outcomes in 18 CKD patients (stages 1-3) and 15 healthy controls using liquid chromatography-mass spectrometry and Mascot-SwissProt for protein identification.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!